238 related articles for article (PubMed ID: 25947575)
1. Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.
Kitajima K; Fukushima K; Miyoshi Y; Nishimukai A; Hirota S; Igarashi Y; Katsuura T; Maruyama K; Hirota S
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1371-7. PubMed ID: 25947575
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
[TBL] [Abstract][Full Text] [Related]
3. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
4. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
5. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
[TBL] [Abstract][Full Text] [Related]
6. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
Kim JY; Lee SH; Kim S; Kang T; Bae YT
Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
[TBL] [Abstract][Full Text] [Related]
7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
9. Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT.
Sasada S; Masumoto N; Suzuki E; Sueoka S; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):831-837. PubMed ID: 30648199
[TBL] [Abstract][Full Text] [Related]
10. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of
Song BI; Kim HW; Won KS
Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
Kajáry K; Tőkés T; Dank M; Kulka J; Szakáll S; Lengyel Z
Nucl Med Commun; 2015 Jan; 36(1):28-37. PubMed ID: 25299471
[TBL] [Abstract][Full Text] [Related]
13. Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study.
Incoronato M; Grimaldi AM; Cavaliere C; Inglese M; Mirabelli P; Monti S; Ferbo U; Nicolai E; Soricelli A; Catalano OA; Aiello M; Salvatore M
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1680-1693. PubMed ID: 29696443
[TBL] [Abstract][Full Text] [Related]
14. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
16. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
[TBL] [Abstract][Full Text] [Related]
17. Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma.
Chiacchio S; Evangelista L; Alsharif A; Manca G; DI Martino F; Negri A; Tredici M; Cervino AR; Puccini G; Filidei E; Ghilli M; Naccarato AG; Roncella M; Volterrani D
Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):101-111. PubMed ID: 26329496
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
20. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]